Why the study?
Do hypercoagulability biomarkers (Procoag-PPL and MRI) predict symptomatic venous thromboembolism in ambulatory patients with lung adenocarcinoma?
Population
150 ambulatory patients with lung adenocarcinoma
Comparison
Measurement of hypercoagulability biomarkers… vs Controls (for baseline biomarker comparison)
Design
Cohort
Authors
Loading...
May aid VTE risk stratification in lung adenocarcinoma; hypothesis-generating and requires prospective validation.
Do hypercoagulability biomarkers (Procoag-PPL and MRI) predict symptomatic venous thromboembolism in ambulatory patients with lung adenocarcinoma?
Incorporation of Procoag-PPL and MRI of thrombin generation into clinical risk assessment models improves the prediction of cancer-associated thrombosis in ambulatory patients with lung adenocarcinoma.
Syrigos et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: